Oramed Pharmaceuticals INC 10-Q quarterly reports

Oramed Pharmaceuticals Inc. filed its Form 10-Q for the period ended June 30, 2026, reporting substantial financial income driven by investment revaluations, alongside an operating loss.

Oramed Pharmaceuticals Inc. reported a significant net income of $38.3 million for Q1 2026, a substantial turnaround from a net loss in the prior year, primarily driven by substantial gains from its investment portfolio.

Oramed Pharmaceuticals reported a significant net income for Q3 2025, driven by substantial revaluation gains from its Scilex and Alpha Tau investments, while terminating its oral insulin joint venture with HTIT and planning a smaller clinical trial.

Oramed Pharmaceuticals reports mixed Q2 2025 results, with a significant increase in net income driven by investment revaluations, despite a delayed oral insulin joint venture and increased R&D spending.

Oramed Pharmaceuticals reports a net loss for Q1 2025, but sees revenue increase due to the HTIT License Agreement and progresses with strategic real estate investments.

Oramed Pharmaceuticals reported its Q3 2024 results, highlighting a strategic review process and ongoing financial activities, including a significant transaction with Scilex Holding Company.

Oramed Pharmaceuticals reported a net income of $10.7 million for the second quarter of 2024, primarily driven by financial income from its investment in Scilex Holding Company, while research and development expenses decreased.

Oramed Pharmaceuticals reported a net income of $1.534 million for the first quarter of 2024, a significant turnaround from a net loss in the same period last year, primarily due to financial income from investments.